Advertisement
X

India Advances In Robotic Heart Surgery, But RHD Must Become The Next Battle

India is advancing in robotic heart surgery, but experts urge prioritising prevention of rheumatic heart disease, which affects millions, via early detection, penicillin and primary care.

As India moves towards becoming a global leader in robotic and minimally invasive heart surgery, a major public health challenge continues to expose the gaps in its cardiac healthcare priorities: rheumatic heart disease (RHD), a largely preventable condition that still affects children and young adults, particularly in economically disadvantaged communities.

The disease, which can begin with an untreated streptococcal throat infection during childhood, can cause irreversible damage to heart valves, leaving children with lifelong disability or requiring major surgery in their twenties and thirties.

While several countries have witnessed a dramatic decline in RHD over the past century through better living conditions, access to antibiotics, early diagnosis and sustained public health interventions, India continues to struggle with the disease, raising questions about why its prevention and elimination have not received the same urgency as other cardiac conditions.

Dr Yugal K Mishra, Chairman, Manipal Institute of Cardiac Sciences, Delhi, said India needed to look beyond the growing burden of coronary artery disease and give greater attention to RHD.

"Everybody talks about heart disease as coronary artery disease and heart attacks. But we still have a huge burden of rheumatic heart disease. When India is aspiring to become a developed nation by 2045, why should we continue to carry this burden?" he said.

Dr Mishra was expressing his concern at a press conference ahead of the three-day international conference from November 20 being organised by the Society of Minimally Invasive Cardiovascular and Thoracic Surgeons of India (SMICTSI) in the national capital. Around 1,200 delegates, including 300 from more than 300 countries, are congregating to deliberate on various fronts in the robotic cardiac surgery sector.

Dr Mishra, who is chairman of the Organising Committee of SMICTSI, pointed out that RHD patients often develop serious valve disease when they are just 25 or 30 years old, at a time when they are expected to support their families and build their careers.

"They should be taking care of their families, but instead they are sick, in hospitals and may require heart surgery," he said.

Drawing attention to geographical differences, he said community outreach programmes and surveys had indicated a greater RHD burden in parts of eastern Uttar Pradesh, Bihar, Madhya Pradesh and other underserved regions compared with relatively better-served areas such as Delhi, Punjab and Mumbai.

Advertisement

Dr Mishra also questioned whether public spending was sufficiently balanced between treatment and prevention. While schemes such as Ayushman Bharat have expanded financial protection for hospitalisation and treatment, he argued that greater investment was needed in basic research, early detection and disease prevention.

His concerns find resonance in a recent article published in the Indian Heart Journal, titled “Elimination of Rheumatic Heart Disease from India: A Clarion Call for Action”, which calls for a reassessment of India's research priorities and public health strategies to tackle the persistent burden of rheumatic heart disease (RHD).

The article underscores the need to move beyond treatment-led interventions and strengthen early detection, primary healthcare, surveillance and prevention, particularly among children and underserved populations.

The authors, Dr Harshit Khare, Dr Aditya Kapoor and Dr Satyendra Tewari from the Department of Cardiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, India, and Dr Rakesh Yadav and Dr Nitish Naik from the Department of Cardiology, All India Institute of Medical Sciences, Delhi, cited the Global Burden of Disease 2023 estimates, which reported around 15 million cases in India, accounting for nearly 40% of the global burden.

Advertisement

The disease has a particularly severe impact on economically disadvantaged communities, where overcrowding, poor living conditions and limited access to timely medical care increase the risk of infection and its complications.

Citing earlier research on neglected disease funding, they highlighted that RHD has received substantially less research support than infectious diseases such as HIV/AIDS, tuberculosis and malaria, despite its significant mortality burden.

RHD often begins with a Group A streptococcal throat infection during childhood. If the infection is not appropriately diagnosed and treated, it can trigger acute rheumatic fever in susceptible children. The resulting inflammatory response can damage the heart valves, and repeated episodes can progressively worsen the condition.

The highest risk of a first episode of acute rheumatic fever is among children aged five to 15 years. However, the burden of established RHD is frequently seen much later, particularly between 25 and 45 years, according to the review.

Timely identification and appropriate antibiotic treatment of Group Streptococcal throat infections can reduce the risk of acute rheumatic fever. Children who develop rheumatic fever also need long-term secondary antibiotic prophylaxis to prevent recurrent attacks and further valve damage, said Dr Yadav.

Advertisement

Strengthening primary healthcare centres, ensuring reliable supplies of penicillin, training frontline health workers and improving referral systems were among various recommendations.

Using portable, handheld echocardiography devices in high-risk regions, community-based awareness programmes involving ASHAs, schools and local health workers can help parents recognise the importance of seeking timely medical care for children with suspected infections, said Naik.

The economic case for prevention is also significant. An extended cost-effectiveness analysis published in The Lancet Global Health in 2023, cited by the review, found that combining secondary and tertiary prevention strategies could prevent four RHD cases per 1,000 people at an additional cost of Rs 23,051 per quality-adjusted life year gained.

The review also highlights the financial burden of valve surgery, which can cost between Rs 2 lakh and Rs 2.73 lakh depending on the procedure and valve prosthesis, although government-supported financial protection schemes have helped cover some of these expenses.

The authors argued that countries such as Cuba, Costa Rica and Tunisia have demonstrated that coordinated prevention programmes can substantially reduce rheumatic fever.

Advertisement

Prof. Dr med Jorg Kempfert, Senior Consultant Cardiac Surgeon in the Department of Cardiothoracic and Vascular Surgery at the German Heart Center Berlin (Deutsches Herzzentrum der Charité) in Berlin, Germany, who is in Delhi for the SMICST conference too, called for early detection and prescribing antibiotics when a streptococcal infection is suspected or confirmed.

“This is the approach that has helped North America and Europe address the problem. It is fundamentally about strengthening general healthcare, particularly for poor and underserved populations. Investing in inexpensive preventive treatment today makes far more economic sense than paying for costly cardiac procedures 20 years later,” he told The Health Outlook.

Published At:
US